We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005
News

Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005

Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005
News

Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Elan Corporation, plc and Transition Therapeutics Inc. have announced the United States Patent and Trademark Office issued US patent number 7,521,481 on April 21, 2009. The patent is entitled “Methods of Preventing, Treating and Diagnosing Disorders of Protein Aggregation,” and generally claims methods for treating Alzheimer’s disease comprising administering scyllo-inositol (ELND005). The patent will expire in the year 2025 or later due to any patent term extensions.

“The issuance of this patent is an important milestone in the development of ELND005, a unique oral compound with a favourable safety profile that crosses the blood-brain barrier and targets the disaggregation of amyloid beta in the brain,” said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.

In 2006, Elan and Transition entered into an exclusive, worldwide collaboration agreement for the joint development and commercialization of ELND005 for the treatment of Alzheimer’s disease and other indications.
Advertisement